Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 6/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | JAK3 | P52333 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 7/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.43 |
| ▸ | CDK4 | P11802 | 2/20 | 0.43 |
| ▸ | CCND1 | P24385 | 2/20 | 0.43 |
| ▸ | F12 | P00748 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167828 | 0.84 | CDK2 (0.46) | SYKJAK2JAK1JAK3CDK2 | |
| SCHEMBL1167433 | 0.83 | CDK2 (0.47) | CDK2CCNE1CDK1CDK4CCND1 | |
| SCHEMBL1167793 | 0.81 | CDK2 (0.44) | SYKJAK2JAK3CDK2CCNE1 | |
| SCHEMBL1167911 | 0.81 | CDK2 (0.44) | SYKJAK2JAK3CDK2CCNE1 | |
| SCHEMBL1167407 | 0.79 | CDK2 (0.49) | SYKJAK2JAK3CDK2CCNE1 | |
| SCHEMBL1168934 | 0.78 | CDK1 (0.63) | AXLSYKJAK2JAK1JAK3 | |
| SCHEMBL1167417 | 0.75 | AXL (0.60) | INSRAXLJAK2JAK1JAK3 | |
| SCHEMBL1167710 | 0.74 | CDK1 (0.69) | INSRAXLSYKJAK2JAK1 | |
| SCHEMBL1168367 | 0.74 | AXL (0.59) | INSRAXLJAK2JAK1JAK3 | |
| SCHEMBL1167740 | 0.72 | AXL (0.57) | INSRAXLJAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | claimed |
| US-8389557-B2 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-7884119-B2 | protein tyrosine kinase receptor inhibitors such as 3-amino -1-(1H-indol-5-yl)carbonyl-5-[4-2-(pyrrolidin-1-yl)ethoxy]phenylamino]-1H-1,2,4-triazole, used for treating diseases and conditions associated with neovascularization and/or cell proliferation | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082131-A1 | TRIAZOLE DERIVATIVES USEFUL AS AXL INHIBITORS | AXL, TYRO3, FLT3 | INSR 508/4885AXL 1/4885SYK 14/4885 |
| US-20070213375-A1 | Triazole derivatives useful as Axl inhibitors | AXL, TYRO3, FLT3 | INSR 291/4885AXL 1/4885SYK 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.